Preliminary Studies Sample Clauses

Preliminary Studies. The Manager will be responsible for conducting studies that consider alternate development paths available to the WA Iron Ore JV either in order to meet the consolidated Demand Forecast or as required by an Owner in accordance with paragraph (b) or in accordance with an approved Business Plan and/or Budget (each a Preliminary Study). Each Preliminary Study will:

Preliminary Studies. A process for the selection of sub-basins and tanks shall be followed to ensure the maximization of the returns on water infrastructure investments. The methodology shall follow three steps: i) an assessment of the water availability in the sub-catchments/tanks; ii) an analysis to see if the available water quantity is sufficient to meet the existing demands for water from different sectors, and (iii) detailed hydrological and water allocation modelling of the sub-basins selected.

Preliminary Studies. If the variation has been requested by the Client pursuant to Clause 7.1 and if the preparation of the assessment of the impact of the requested variation requires the Consultant to carry out searches, tests, investigations and/or to take any other reasonable prior measures, the Consultant shall first submit as soon as reasonably possible to the Client an estimate of the costs and fees that will have to be borne by the Client for the study of the variation and of the time necessary to perform the required preliminary tasks. Within ten (10) Days as from the submission of those estimates, the Client shall notify its decision to go ahead with the study of the variation. In, the absence of any notification by the Client within the allocated ten (10)-Day time period allocated to do so, the Client shall be deemed to have approved the estimates provided by the Consultant and to have instructed it to initiate the carrying out of the preliminary tasks identified in the Consultant submission. If the variation is requested by the Consultant pursuant to Clause 7.2, the costs and fees for preliminary searches, tests, investigations and/or other reasonable prior measures will be duly taken into account in the assessment of the impact of the variation on the Remuneration and/or time schedule for the supply of the Services.

Preliminary Studies. Not required for Clinical and Postdoctoral Fellow Applications but encouraged if you have it . Subsequent requests for funds for the same project must include preliminary studies. Use this section to provide an account of the principal investigator’s preliminary studies pertinent to the application and/or any other information that will help to establish the experience and competence of the investigator to pursue the proposed project.

Preliminary Studies. Task 2.1

Preliminary Studies. “Discuss [your team’s] preliminary studies, data, and or experience pertinent to this application.”1 You may wish to highlight these data in particular: The preliminary data that supports your hypothesis The preliminary data that supports your ability to complete the work successfully This section is typically about half to three-quarters of a page in length and often includes tables or figures. “Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project.”1 This section details the approach and typically answers the following questions: What will be done and how will you do it (Research Design, Analytic Strategy, Timeline, etc.)? What are the possible challenges, expected outcomes (e.g., including but not limited to research findings, potential publications, and external grant funding), and future directions? In addition to the above standard sections that would be included in an NIH grant, strong applications also should clearly emphasize: The potential for capacity building at the foreign site How the project would benefit the foreign site ▇▇’s career This section is typically about two to two and a half pages in length and often includes tables or figures. Literature Cited (not included in 4 page limit) INTERNATIONAL RESEARCH OBJECTIVES The SD CFAR seeks to fund international research that can be completed in a timely manner, contribute to the careers of international HIV/AIDS investigators, and build capacity for future HIV/AIDS research. Please respond to the following items so we can evaluate your proposed study in terms of our overall objectives. Delete all highlighted instructions before submitting your application. Previously Funded CFAR Grants Have you (the international Principal Investigator) previously received one or more grants from the SD CFAR? If YES, please provide the information requested below. Title of previously funded Pilot grant(s) Year(s) awarded Publications and subsequent grants resulting from previously funded CFAR International Pilot grants.

Preliminary Studies. [information has been omitted from the filed version of this License Agreement]

Preliminary Studies. Dose-response curve of EAE suppression in LA-treated mice. LA suppresses EAE, the animal model of MS, in a dose-dependent fashion. In a study of EAE mice treated with LA before disease onset, LA in doses of 100 mg/kg/day, 50 mg/kg/day, and 20 mg/kg/day were all effective in suppressing EAE (19). An LA dose of 20 mg/kg/day suppressed EAE development by almost 50% (according to Cumulative Disease Scores scores), a dose of 50 mg/kg/day suppressed EAE by ~80%, and a dose of 100 mg/kg/day suppressed EAE by 100% over 10 days (Fig.1). PK studies in EAE and humans have determined the human equivalent dose to the therapeutically effective dose in EAE. Two PK studies of LA in people with MS were conducted at OHSU and determined that doses of 1200mg taken with food were easily detectable LA levels in the serum and had reasonable gastrointestinal tolerability (15, 17). A formulation from the PK studies was used in the pilot LA in SPMS trial and will be used again in the current trial of LA in PMS. Spain et al conducted a single-center, 2-year randomized, double-blind, placebo-controlled phase 2 trial (n=51) of daily oral LA in SPMS (18). The LA cohort demonstrated a 68% reduction in the annualized rate of whole brain atrophy (0.21% vs -0.65%, p = 0.002, Fig 4). Although not powered to detect clinical outcomes, the LA cohort had a trend toward improvement in walking speed in the T25FW (-0.54 SD 0.36 vs 0.14 SD 0.25, p = Figure 4. LA reduces brain atrophy in SPMS participants using intention-to- treat analysis.

Preliminary Studies. Both co-investigators, ▇▇. ▇▇▇▇▇▇ and ▇▇. ▇▇▇▇▇, are involved with genetic research studies at Children’s Hospital Boston that involve whole genome sequencing. The analysis of the sequencing data has been complex, due to the large amount of data and the number of potential variants identified. The difficult nature of analysis is increased by the fact that there is no consensus on what types of results should be reported back to participants.